EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study

Sophie L Preuß iD, Katja Bieber iD, Artem Vorobyev, Andreas Recke iD, Eva Lotta Moderegger, Henner Zirpel iD, Evelyn Gaffal, Diamant Thaçi, Khalaf Kridin iD, Ralf J Ludwig

Journal of the European Academy of Dermatology and Venereology · 2025-09 · 39 (9) · 1576-1587

DOI: 10.1111/jdv.20670 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 02.04.2025. Verfasst von Sophie L Preuß und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Medical Centre of the State of Schleswig-Holstein (UKSH), Lübeck, Germany. Hauptthemen laut MEDLINE: Chronic Disease, Antibodies, Monoclonal, Humanized, Pregnancy Complications, Maternal Exposure. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.

Objectives

To retrospectively assess the risk of APOs in dupilumab‐treated pregnant women in a large real‐world database.

Methods

Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy‐induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan–Meier method, outcome differences the log‐rank test and hazard ratios (HR) the Cox regression model.

Results

During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03–0.45, p = 0.0002 ) and ‘any APO’ (HR: 0.53, CI: 0.33–0.84, p = 0.0067) in the dupilumab‐treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab‐treated and untreated women up to 6 months before pregnancy or during the postpartum period.

Conclusions

This large‐scale propensity‐matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic DiseaseAntibodies, Monoclonal, HumanizedPregnancy ComplicationsMaternal ExposureDrug-Related Side Effects and Adverse ReactionsPropensity ScoreRetrospective StudiesDatabases, FactualHumansFemalePregnancyYoung AdultAdultUnited StatesRisk FactorsKaplan-Meier EstimateProportional Hazards ModelsPregnancy Outcome

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, University Medical Centre of the State of Schleswig-Holstein (UKSH), Lübeck, Germany.
  • Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
  • Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Unit of Dermatology and Skin Research Laboratory, Barch Padeh Medical Center, Poriya, Israel.

ORCID-Profile: Sophie L Preuß, Katja Bieber, Andreas Recke, Henner Zirpel, Khalaf Kridin

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Preuß, S. L., Bieber, K., Vorobyev, A., Recke, A., Moderegger, E. L., Zirpel, H., Gaffal, E., Thaçi, D., Kridin, K., & Ludwig, R. J. (2025). Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study. Journal of the European Academy of Dermatology and Venereology, 39(9), 1576-1587. https://doi.org/10.1111/jdv.20670

Vancouver

Preuß SL, Bieber K, Vorobyev A, Recke A, Moderegger EL, Zirpel H, et al. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study. Journal of the European Academy of Dermatology and Venereology. 2025;39(9):1576-1587. doi:10.1111/jdv.20670

BibTeX
@article{Preu2025,
  author = {Preuß, Sophie L and Bieber, Katja and Vorobyev, Artem and Recke, Andreas and Moderegger, Eva Lotta and Zirpel, Henner and Gaffal, Evelyn and Thaçi, Diamant and Kridin, Khalaf and Ludwig, Ralf J},
  title = {Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity‐matched cohort study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {9},
  pages = {1576--1587},
  doi = {10.1111/jdv.20670}
}
Kostenlos starten →